Synapse loss is the principal cause of cognitive decline in Alzheimer’s disease (AD) and related disorders ( LBD, ADRD). The study reports that RAP-103, a CCR5 antagonist, at exceedingly low concentrations, prevents amyloid beta destruction of synapses in cultured rodent and human neurons, effects which are expected to slow, prevent, possibly even reverse cognitive decline. [Kuhn, 2024]